Abstract
Adequate correction of many acquired and congenital heart valve is impossible without artificial heart valves.
For implantation in the tricuspid position both biological and mechanical prostheses are used. Mechanical
valves are characterized by along life, but by courtesy of the high frequency of prosthesis-depend complications
and necessity of anticoagulants, in most clinics biological valves are preferred. The disadvantage of biological
prostheses, especially in pediatric patients is early structural degeneration, that requires reoperation
for valve replacement. Average life of biological prostheses in the tricuspid position is less than 20 years. This
report describes the clinical case of tricuspid valve re-replacement after 34 years from primary implantation
of a biological prosthesis for the correction of Ebstein's anomaly.
References
- Бокерия Л.А., Каграманов И.И., Кокшенев И.В.,
Бритиков Д.В. Биоматериалы в сердечно-сосудистой
хирургии. М.: НЦССХ им. А.Н. Бакулева
РАМН; 2009.
- Van Slooten Y.J., Freling H.G., van Mellea J.P.,
Mulderc B.J., Jongbloedf M.R., Ebelsb T. et al.
Long-term tricuspid valve prosthesis-related complications
in patients with congenital heart disease.
Eur. J. Cardiothorac. Surg. 2013; 45: 83-9.
- Garatti A., Nano G., Bruschi G., Canziani A, Colombo
T., Frigiola A. et al. Twenty-five year outcomes of
tricuspid valve replacement comparing mechanical
and biologic prostheses. Ann. Thorac. Surg. 2012; 93:
1146-53.
- Kiziltan H.T., Theodoro D.A., Warnes C.A.,
O'Leary P. W., Anderson B.J., Danielson G.K. Late
results of bioprosthetic tricuspid valve replacement
in Ebstein's anomaly. Ann. Thorac. Surg. 1998; 66:
1539-45.
- Stanley J., Chandrasekhar R. Prosthetic valve
replacement in Ebstein's malformation: 30-year follow-
uр. Ann. Thorac. Surg. 1999; 68: 556-7.
- Baumgartner H., Bonhoeffer P., De Groot N.M.,
de Haan F., Deanfield J.E., Galie N. et al. ESC
guidelines for the management of grown-up congenital
heart disease (new version 2010). Eur. Heart
J. 2010; 31: 2915-57.
